166 related articles for article (PubMed ID: 11011846)
1. Mild hyperhomocysteinemia is an independent risk factor of arterial vascular disease.
Boers GH
Semin Thromb Hemost; 2000; 26(3):291-5. PubMed ID: 11011846
[TBL] [Abstract][Full Text] [Related]
2. Vitamin supplements and cardiovascular risk: review of the randomized trials of homocysteine-lowering vitamin supplements.
Clarke R; Armitage J
Semin Thromb Hemost; 2000; 26(3):341-8. PubMed ID: 11011852
[TBL] [Abstract][Full Text] [Related]
3. Homocysteine--relevant for atherogenesis?
Kircher T; Sinzinger H
Wien Klin Wochenschr; 2000 Jun; 112(12):523-32. PubMed ID: 10953870
[TBL] [Abstract][Full Text] [Related]
4. Hyperhomocysteinemia, atherosclerosis and thrombosis.
Cattaneo M
Thromb Haemost; 1999 Feb; 81(2):165-76. PubMed ID: 10063987
[TBL] [Abstract][Full Text] [Related]
5. Homocysteine and renal disease.
van Guldener C; Robinson K
Semin Thromb Hemost; 2000; 26(3):313-24. PubMed ID: 11011849
[TBL] [Abstract][Full Text] [Related]
6. [Homocysteinemia and vascular disease--a new risk factor is born].
Reis RP; Luís AS
Rev Port Cardiol; 1999 May; 18(5):507-14. PubMed ID: 10418265
[TBL] [Abstract][Full Text] [Related]
7. Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases.
Stanger O; Herrmann W; Pietrzik K; Fowler B; Geisel J; Dierkes J; Weger M
Z Kardiol; 2004 Jun; 93(6):439-53. PubMed ID: 15252738
[TBL] [Abstract][Full Text] [Related]
8. Preventive health care, 2000 update: screening and management of hyperhomocysteinemia for the prevention of coronary artery disease events. The Canadian Task Force on Preventive Health Care.
Booth GL; Wang EE
CMAJ; 2000 Jul; 163(1):21-9. PubMed ID: 10920726
[TBL] [Abstract][Full Text] [Related]
9. [Hyperhomocysteinemia as a risk factor for venous thrombosis].
Willems HP; den Heijer M; Blom HJ; Gerrits WB; Rosendaal FR; Bos GM
Ned Tijdschr Geneeskd; 1999 Mar; 143(11):552-6. PubMed ID: 10321272
[TBL] [Abstract][Full Text] [Related]
10. [Homocysteine and diabetic macroangiopathy].
Araki A
Nihon Rinsho; 2006 Nov; 64(11):2153-8. PubMed ID: 17087311
[TBL] [Abstract][Full Text] [Related]
11. [Hyperhomocysteinemia, a risk factor for atherosclerosis: causes and effects].
Weiss N; Pietrzik K; Keller C
Dtsch Med Wochenschr; 1999 Sep; 124(38):1107-13. PubMed ID: 10535040
[No Abstract] [Full Text] [Related]
12. [Homocysteine--a risk factor for atherosclerosis].
Debreceni L
Orv Hetil; 2001 Jul; 142(27):1439-44. PubMed ID: 11481906
[TBL] [Abstract][Full Text] [Related]
13. Hyperhomocysteinemia as a risk factor for arterial and venous disease. A review of evidence and relevance.
Boers GH
Thromb Haemost; 1997 Jul; 78(1):520-2. PubMed ID: 9198207
[TBL] [Abstract][Full Text] [Related]
14. Controlled trials of very high dose folic acid, vitamins B12 and B6, intravenous folinic acid and serine for treatment of hyperhomocysteinemia in ESRD.
Gonin JM; Nguyen H; Gonin R; Sarna A; Michels A; Masri-Imad F; Bommareddy G; Chassaing C; Wainer I; Loya A; Cary D; Barker LF; Assefi A; Greenspan R; Mahoney D; Wilcox CS
J Nephrol; 2003; 16(4):522-34. PubMed ID: 14696754
[TBL] [Abstract][Full Text] [Related]
15. Vascular complications of severe hyperhomocysteinemia in patients with homocystinuria due to cystathionine beta-synthase deficiency: effects of homocysteine-lowering therapy.
Yap S; Naughten ER; Wilcken B; Wilcken DE; Boers GH
Semin Thromb Hemost; 2000; 26(3):335-40. PubMed ID: 11011851
[TBL] [Abstract][Full Text] [Related]
16. Hyperhomocysteinemia: clinical and therapeutical involvement in venous thrombosis.
Hoţoleanu C; Porojan-Iuga M; Rusu ML; Andercou A
Rom J Intern Med; 2007; 45(2):159-64. PubMed ID: 18333369
[TBL] [Abstract][Full Text] [Related]
17. [Homocysteine and cardiovascular risk].
Auer J; Berent R; Weber T; Lassnig E; Eber B
Wien Med Wochenschr; 2001; 151(1-2):25-8. PubMed ID: 11234594
[TBL] [Abstract][Full Text] [Related]
18. No effect of homocysteine-lowering therapy on vascular inflammation and haemostasis in peripheral arterial occlusive disease.
Schernthaner GH; Plank C; Minar E; Bieglmayer C; Koppensteiner R; Schernthaner G
Eur J Clin Invest; 2006 May; 36(5):333-9. PubMed ID: 16634837
[TBL] [Abstract][Full Text] [Related]
19. Rationale and design for the CARDIOVIT Study (Cardiovit, Atherosclerotic vascular disease and hypeRhomocysteinemia: an epiDemiological study in Indians, additionally evaluating the effect of Oral VITamin supplementation).
Shenoy KT; Lena KB; Sali N; Syam S; Shenoy ST; Rajadhyaksha VD; Pai GP; Shaikh AA;
Curr Med Res Opin; 2006 Apr; 22(4):641-8. PubMed ID: 16684424
[TBL] [Abstract][Full Text] [Related]
20. Can dietary supplements with folic acid or vitamin B6 reduce cardiovascular risk? Design of clinical trials to test the homocysteine hypothesis of vascular disease.
Clarke R; Collins R
J Cardiovasc Risk; 1998 Aug; 5(4):249-55. PubMed ID: 9919473
[No Abstract] [Full Text] [Related]
[Next] [New Search]
